Description: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
Home Page: www.astriatx.com
ATXS Technical Analysis
100 High Street
Boston,
MA
02110
United States
Phone:
617 349 1971
Officers
| Name | Title |
|---|---|
| Ms. Jill C. Milne Ph.D. | Co-Founder, CEO, Pres & Director |
| Mr. Noah Clauser CPA | Chief Financial Officer |
| Dr. Andrew J. Nichols Ph.D. | Chief Scientific Officer |
| Mr. Benjamin S. Harshbarger J.D. | Chief Legal Officer |
| Ms. Keri McGrail | Sr. VP of HR |
| Ms. Andrea L. Matthews | Sr. VP of Corp. Affairs |
| Mr. Andrew A. Komjathy | Chief Commercial Officer |
| Dr. Anthony Christopher Stevens M.D. | Interim Chief Medical Officer |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.3959 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2015-06-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |